News

The Phase II trial involves treatment of patients with advanced, primary liver cancer refractory to standard therapies. Patients are randomized to receive treatment at one of two dose

The Phase II clinical trial, which began at the end of December 2008, is designed as a four-week, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability

The three new brands are Pacnex wash, a topical treatment for acne; Sumaxin cleansing pads, a topical treatment for acne, rosacea and seborrheic dermatitis; and Uramaxin nail gel,

The acquisition has been approved by Ablation Frontiers’s shareholders, and is subject to regulatory clearance. The transaction is expected to close in Medtronic’s fourth fiscal quarter, ending April

Under the terms of the agreement, Bayer Schering Pharma will pay Micromet a E4.5 million fee to secure a one year option on a specific BiTE antibody. Bayer

The trial will evaluate the efficacy of PRX302 versus placebo using the optimal treatment volume established in the open-label Phase II study results announced in November, 2008. The

Under the terms of the merger agreement, Targanta shareholders will receive $2 in cash up front for each common share tendered, or approximately $42 million. Targanta shareholders may

This case was initiated by CoreValve in the UK in September 2007. In response, Edwards counter-sued, claiming infringement of the patent. While the court upheld Edwards’s patent, it

Under the terms of the agreement, Santaris Pharma will receive an upfront payment of $7 million in cash and Wyeth will make a $10 million equity investment in